Teva Pharmaceutical Industries Limited
NYSE:TEVADrug Manufacturers - Specialty & Generic
-$1.09 today
- Market cap
- $49.28B
- Beta
- 0.85
- P/E (TTM)
- 23.1
- EPS (TTM)
- $1.36
Volume 8.86M
Average 6.22M
TEVA Account Payables
Amounts the company owes suppliers for goods and services received.
Teva Pharmaceutical Industries LimitedNYSE: TEVA
Account Payables · Q2 FY2026 · quarter ended Jun 2026
Account payables rises 8.9% from a year ago
Account payables stood at $2.72B at the end of Q2 FY2026, up 8.9% from a year earlier and up 4.8% from the prior quarter. Over 3 fiscal years it compounded at +10.3% a year.
Context
- Account payables amounted to 6.8% of total assets at the end of Q2 FY2026, up 0.6 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +8.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.53B USD
- Year-over-year change
- +14.9%
- 4-year CAGR
- +10.7%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.53B | +14.9% |
| FY2024 | 2024-12-31 | 2.2B | -15.3% |
| FY2023 | 2023-12-31 | 2.6B | +37.9% |
| FY2022 | 2022-12-31 | 1.89B | +11.9% |
| FY2021 | 2021-12-31 | 1.69B | — |
Account Payables vs competitors
How TEVA compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +8.9% is the 2nd highest of 5, against a peer median of -8.0%.
- Account payables amounts to 6.8% of total assets for TEVA, versus a peer median of 6.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | ₹36.24B INR | -10.0% | +22.4% | 6.3% | |
| Jun 2026 | $2.72B USD | +8.9% | +10.3% | 6.8% | |
| Jun 2026 | $1.24B USD | -6.0% | +3.8% | 3.5% | |
| Jun 2026 | $244.23M USD | -63.4% | +15.1% | 6.5% | |
| Mar 2026 | $97.87M USD | +44.2% | +36.9% | 6.9% | |
| Peer median (excluding TEVA) | — | -8.0% | +18.8% | 6.4% | |
Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.17B | 2.8B | 3.23B | 3.3B | 3.56B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 4.53B | 3.7B | 3.41B | 3.06B | 3.71B |
| Inventory | 3.82B | 3.83B | 4.02B | 3.01B | 3.18B |
| Other Current Assets | 986M | 559M | 575M | 2.18B | 2.38B |
| Total Current Assets | 12.57B | 12.05B | 12.49B | 12.55B | 13.95B |
| Property, Plant & Equipment (Net) | 6.48B | 6.16B | 6.15B | 4.95B | 4.42B |
| Goodwill | 20.04B | 17.63B | 17.18B | 15.15B | 16B |
| Intangible Assets | 7.47B | 6.27B | 5.39B | 4.42B | 3.78B |
| Long-term Investments | 0 | 0 | 8M | 0 | 0 |
| Tax Assets | 596M | 1.46B | 1.81B | 1.8B | 2.19B |
| Other Non-current Assets | 515M | 441M | 462M | 462M | 404.99M |
| Total Non-current Assets | 35.09B | 31.96B | 30.99B | 26.77B | 26.8B |
| Total Assets | 47.67B | 44.01B | 43.48B | 39.33B | 40.75B |
| Account Payables | 1.69B | 1.89B | 2.6B | 2.2B | 2.53B |
| Short-term Debt | 1.43B | 2.11B | 1.67B | 1.78B | 1.82B |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.71B | 5.32B | 5.2B | 6.02B | 8.37B |
| Total Current Liabilities | 11.03B | 11.47B | 12.25B | 12.8B | 13.46B |
| Long-term Debt | 21.62B | 19.1B | 18.16B | 16B | 15.27B |
| Deferred Tax Liabilities | 784M | 548M | 606M | 483M | 296M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.58B | 3.94B | 4.02B | 4.03B | 3.52B |
| Total Non-current Liabilities | 25.4B | 23.94B | 23.11B | 20.81B | 19.38B |
| Total Liabilities | 36.42B | 35.41B | 35.35B | 33.61B | 32.83B |
| Common Stock | 57M | 57M | 57M | 58M | 58M |
| Retained Earnings | (10.53B) | (12.98B) | (13.53B) | (15.17B) | (13.76B) |
| Accumulated OCI | (2.68B) | (2.84B) | (2.7B) | (3.15B) | (2.39B) |
| Other Stockholders Equity | 0 | 0 | 1M | 0 | 0 |
| Minority Interest | 966M | 794M | 620M | 347M | 4M |
| Total Equity | 11.24B | 8.6B | 8.13B | 5.72B | 7.91B |
| Total Debt | 23.46B | 21.56B | 20.15B | 18.08B | 17.38B |
| Net Debt | 21.29B | 18.76B | 16.93B | 14.78B | 13.83B |
Teva Pharmaceutical Industries Limited
NYSE:TEVA
Intrinsic Alpha fair value
Locked
Current Price
$42.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.